• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Inscripta Raises $125M in Series D Financing to Accelerate Commercialization of Revolutionary Digital Genome Engineering Platform

Share:

December 16, 2019

Inscripta Logo (PRNewsfoto/Inscripta, Inc.)

Inscripta, Inc., today announced the company has raised $125 million in a Series D financing with support from the company’s existing investors and new investors JS Capital Management LLC and Oak HC/FT. Paladin Capital Group led the round, bringing the total amount raised by the company to $259.5 million. The new funds will be used to accelerate applications expansion and commercialization of the company’s revolutionary Onyx™ Digital Genome Engineering platform.

The Onyx platform is the world’s first fully automated benchtop instrument for genome-scale engineering. Consisting of an instrument, consumables, software, and assays, it enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow. The new platform offers immediate and significant benefits that will give scientists in genome discovery, healthcare, bio-industrial materials development and manufacturing, and sustainability the power to design, engineer, evaluate, and track results of genome engineering experiments in their own labs.

“We have been extremely impressed with the Inscripta team’s passion, focus, and relentless execution, which culminated in the successful launch of the Onyx Digital Genome Engineering platform,” said Paul Conley, PhD, Managing Director & Venture Studio Director at Paladin Capital Group. “We are thrilled to lead this funding round and believe Inscripta’s technology will be essential for enabling biology to become the driving force of our economy.”

“The overwhelming interest we received with the recent launch of our Onyx platform along with this significant funding offer tremendous validation of our novel approach to genome engineering and its power to unlock the full potential of the emerging bioeconomy,” said Kevin Ness, PhD, CEO of Inscripta. “We are excited to see that by overcoming the limitations of existing CRISPR-based gene editing, our digital genome engineering tools are already having a significant impact by enabling researchers to design experiments that were previously impossible. The new funding provides us with the resources to ramp up faster to meet the anticipated high demand for our platform.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: Business Wire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Innovative MedTech Acquires RX Vitality in a Share ExchangeInnovative MedTech Announces AcquisitionInnovative MedTech Acquires RX Vitality in a Share ExchangeInnovative MedTech Announces Acquisition
  • MedAnswers Raises $5 Million Seed Round and Launches First Social Media Feed with Scientifically and Clinically Validated Fertility Resources On The FertilityAnswers AppMedAnswers Raises $5 Million Seed Round and Launches First Social Media Feed with Scientifically and Clinically Validated Fertility Resources On The FertilityAnswers App
  • CommonSpirit Health Personalizes and Automates the Medical Intake Experience for Patients and Providers in Partnership with Notable HealthCommonSpirit Health Personalizes and Automates the Medical Intake Experience for Patients and Providers in Partnership with Notable Health
  • RCM: 4 Must-Haves of a Revenue Integrity SolutionRCM: 4 Must-Haves of a Revenue Integrity Solution
  • BBH Capital Partners Exits Investment In KabaFusion Holdings LLCBBH Capital Partners Exits Investment In KabaFusion Holdings LLC
  • Bamboo Health Streamlines Care Collaboration for Oak Street Health for Real-Time Patient Event NotificationsBamboo Health Streamlines Care Collaboration for Oak Street Health for Real-Time Patient Event Notifications
  • FDA Recognizes Standards for Medical Device Interoperability, Safety Assurance CasesFDA Recognizes Standards for Medical Device Interoperability, Safety Assurance Cases
  • Christianacare Partners with Cedar to Personalize Patient Financial ExperienceChristianacare Partners with Cedar to Personalize Patient Financial Experience

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications